Aikido pharma reports improved manufacturing process and new united states patent for pancreatic drug

New york , march 3, 2022 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki) ("aikido" or the "company") today reported an improvement in the manufacturing process for its pancreatic cancer drug, dha-dfdc, licensed from the university of texas at austin. the company also reported the issuance of an additional u.s. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug.
DOMH Ratings Summary
DOMH Quant Ranking